
1. j med chem. 2019 jan 24;62(2):1022-1035. doi: 10.1021/acs.jmedchem.8b01769. epub 
2018 dec 24.

structure-activity relationship studies plasmodium life cycle profiling
identifies pan-active n-aryl-3-trifluoromethyl pyrido[1,2- a]benzimidazoles which
are efficacious vivo mouse model malaria.

mayoka g(1), njoroge m(2), okombo j(1), gibhard l(2), sanches-vaz m(3), fontinha 
d(3), birkholtz lm(4), reader j(4), van der watt m(4), coetzer tl(5), lauterbach 
s(5), churchyard a(5), bezuidenhout b(5), egan tj(1)(6), yeates c(7), wittlin
s(8)(9), prudêncio m(3), chibale k(1)(10)(6).

author information: 
(1)department chemistry , university cape town , rondebosch 7701 , south
africa.
(2)drug discovery development centre (h3d), division clinical
pharmacology, department medicine , university cape town , observatory ,
cape town 7925 , south africa.
(3)instituto de medicina molecular joão lobo antunes, faculdade de medicina ,
universidade de lisboa , av. prof. egas moniz , 1649-028 lisbon , portugal.
(4)department biochemistry, genetics microbiology, institute for
sustainable malaria control , university pretoria , private bag x20 , hatfield
0028 , south africa.
(5)wits research institute malaria, faculty health sciences , university
of witwatersrand national health laboratory service , johannesburg 2193 ,
south africa.
(6)institute infectious disease molecular medicine , university cape
town , rondebosch 7701 , south africa.
(7)inpharma consultancy, 6 dudley hill close , welwyn , hertfordshire al60qq ,
u.k.
(8)department medical parasitology infection biology , swiss tropical 
public health institute , basel , switzerland.
(9)university basel , basel , switzerland.
(10)south african medical research council, drug discovery development
research unit , university cape town , rondebosch 7701 , south africa.

structure-activity relationship studies involving n-aryl-3-trifluoromethyl
pyrido[1,2- a]benzimidazoles (pbi) identified several compounds possessing potent
in vitro activities asexual blood, liver, gametocyte stages of
the plasmodium parasite cross-resistance chloroquine. frontrunner lead
compounds good vitro absorption, distribution, metabolism, excretion 
(adme) profiles subjected vivo proof-of-concept studies nmri mice
harboring rodent p. berghei infection. led identification of
compounds 10 49, effecting 98% 99.93% reduction parasitemia mean 
survival days 12 14, respectively, oral dose 4 × 50 mg/kg. in
vivo pharmacokinetics studies 10 revealed slow absorption, low volume of
distribution, low clearance profiles. furthermore, series displayed a
low propensity inhibit human ether-a-go-go-related gene (herg) potassium
ion channel whose inhibition associated cardiotoxicity.

doi: 10.1021/acs.jmedchem.8b01769 
pmid: 30562027  [indexed medline]

